Literature DB >> 36214890

Current trends in diagnostic and therapeutic management of the axilla in breast cancer patients receiving neoadjuvant therapy: results of the German-wide NOGGO MONITOR 24 survey.

Maggie Banys-Paluchowski1, Michael Untch2, Natalia Krawczyk3, Maria Thurmann2, Thorsten Kühn4, Jalid Sehouli5,6, Maria Luisa Gasparri7,8, Jana de Boniface9,10, Oreste Davide Gentilini11, Elmar Stickeler12, Nina Ditsch13, Achim Rody14, Peter Paluchowski15, Jens-Uwe Blohmer16.   

Abstract

PURPOSE: In the last 2 decades, the optimal management of the axilla in breast cancer patients receiving neoadjuvant chemotherapy (NACT) has been one of the most frequently discussed topics. Little is known about the attitudes of surgeons/radiologists towards new developments such as targeted axillary dissection. Therefore, the NOGGO conducted a survey to evaluate the current approach to axillary management.
METHODS: A standardized digital questionnaire was sent out to > 200 departments in Germany between 7/2021 and 5/2022. The survey was supported by EUBREAST.
RESULTS: In total, 116 physicians completed the survey. In cN0 patients scheduled to receive NACT, 89% of respondents recommended sentinel lymph node biopsy (SLNB) after NACT. In case of ypN1mi(sn), 44% advised no further therapy, while 31% proposed ALND and 25% axillary irradiation. 64% of respondents recommended a minimally invasive axillary biopsy to cN + patients. TAD was used at the departments of 82% of respondents and was offered to all cN + patients converting to ycN0 by 57% and only to selected patients, usually based on the number of suspicious nodes at time of presentation, by 43%. The most common marking technique was a clip/coil. 67% estimated that the detection rate of their marker was very good or good.
CONCLUSION: This survey shows a heterogenous approach towards axillary management in the neoadjuvant setting in Germany. Most respondents follow current guidelines. Since only two-thirds of respondents experienced the detection rate of the marker used at their department as (very) good, future studies should focus on the comparative evaluation of different marking techniques.
© 2022. The Author(s).

Entities:  

Keywords:  Breast cancer; Breast ultrasound; Neoadjuvant chemotherapy; Survey; Targeted axillary dissection

Year:  2022        PMID: 36214890     DOI: 10.1007/s00404-022-06804-w

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.493


  8 in total

1.  Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?

Authors:  Tracy-Ann Moo; Marcia Edelweiss; Sabina Hajiyeva; Michelle Stempel; Monica Raiss; Emily C Zabor; Andrea Barrio; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2018-03-23       Impact factor: 5.344

2.  Heterogeneous Responses of Axillary Lymph Node Metastases to Neoadjuvant Chemotherapy are Common and Depend on Breast Cancer Subtype.

Authors:  Antonia Glaeser; Hans-Peter Sinn; Carlos Garcia-Etienne; Fabian Riedel; Sarah Hug; Benedikt Schaefgen; Michael Golatta; Andre Hennigs; Manuel Feisst; Christof Sohn; Joerg Heil
Journal:  Ann Surg Oncol       Date:  2019-10-11       Impact factor: 5.344

3.  Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.

Authors:  Mila Donker; Marieke E Straver; Jelle Wesseling; Claudette E Loo; Margaret Schot; Caroline A Drukker; Harm van Tinteren; Gabe S Sonke; Emiel J Th Rutgers; Marie-Jeanne T F D Vrancken Peeters
Journal:  Ann Surg       Date:  2015-02       Impact factor: 12.969

4.  Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.

Authors:  Muriel Brackstone; Fulvia G Baldassarre; Francisco E Perera; Tulin Cil; Mariana Chavez Mac Gregor; Ian S Dayes; Jay Engel; Janet K Horton; Tari A King; Anat Kornecki; Ralph George; Sandip K SenGupta; Patricia A Spears; Andrea F Eisen
Journal:  J Clin Oncol       Date:  2021-07-19       Impact factor: 44.544

5.  Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.

Authors:  Armando E Giuliano; Karla V Ballman; Linda McCall; Peter D Beitsch; Meghan B Brennan; Pond R Kelemen; David W Ollila; Nora M Hansen; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Kelly K Hunt; Monica Morrow
Journal:  JAMA       Date:  2017-09-12       Impact factor: 56.272

6.  Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature.

Authors:  Malgorzata Banys-Paluchowski; Ines Verena Gruber; Andreas Hartkopf; Peter Paluchowski; Natalia Krawczyk; Mario Marx; Sara Brucker; Markus Hahn
Journal:  Arch Gynecol Obstet       Date:  2020-01-02       Impact factor: 2.344

7.  Lost clips after targeted lymph node biopsy in breast cancer patients: Follow-up of the CLIP-study.

Authors:  Steffi Hartmann; Angrit Stachs; Bernd Gerber; Hellen Knauerhase; Frank Kamin; Günther Kundt; Toralf Reimer
Journal:  Eur J Surg Oncol       Date:  2021-04-30       Impact factor: 4.424

8.  Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA study.

Authors:  Steffi Hartmann; Thorsten Kühn; Michael Hauptmann; Elmar Stickeler; Marc Thill; Michael P Lux; Sarah Fröhlich; Franziska Ruf; Sibylle Loibl; Jens-Uwe Blohmer; Hans-Christian Kolberg; Elisabeth Thiemann; Michael Weigel; Christine Solbach; Gabriele Kaltenecker; Peter Paluchowski; Michael G Schrauder; Stefan Paepke; Dirk Watermann; Markus Hahn; Maria Hufnagel; Jutta Lefarth; Michael Untch; Maggie Banys-Paluchowski
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-09-13       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.